Cortical NMDA receptor properties and membrane fluidity are altered in alzheimer’s disease

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 4, 1996, Pages 210-214

  Scheuer, K ^a   Maras, A ^a   Gattaz, W F ^a   Cairns, N ^b   Forstl H ^a   Muller W E ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Alzheimer s disease; Cortical areas; Membrane fluidity; NMDA receptor density

Indexed keywords

BRAIN RECEPTOR; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; FRONTAL CORTEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEMBRANE FLUIDITY; NEUROFIBRILLARY TANGLE; PARIETAL LOBE; PRIORITY JOURNAL; RECEPTOR DENSITY; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANISOTROPY; CELL MEMBRANE; CEREBRAL CORTEX; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FLUORESCENT DYES; HUMANS; LIPID BILAYERS; MALE; MEMBRANE FLUIDITY; MIDDLE AGED; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0029793007     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106881     Document Type: Article

References (30)

1. Pearson AM, Wsiri MM, Hioms RW, Wilcock GK, Powell TPS: Anatomical correlates of the distribution of the pathological changes in the neocortcx in Alzheimer disease. Proc Nall Acad Sci USA 1985;82:4531-4534.
2. Procter AW, Palmer AM, Stratmann GC, Bowen DM: Glutamate/aspartate-releasing neurons in Alzheimer’s disease (letter). N Engl J Med 1986;314:1711-1712.
3. Jones EG: Neurotransmitter in the cerebral cortex. J Ncurosurg 1986;65:135-153.
4. Cowbum RF, Hardy JA, Roberts PJ, Briggs R: Regional distribution of prc- and postsynaptic glutamatcrgic function in Alzheimer’s disease. Brain Res 1988;452:403-407.
5. Gottfries CG: Ncurochcmical aspects on aging and diseases with cognitive impairment. J Neurosci Res 1990;27:541-547.
6. Maragos WF, Greenamyre JT: Penney JB Jr, Young AB: Glutamate dysfunction in Alzheimer’s disease. Trends Neurosci 1987; 10:65-68.
7. Deulsch SJ. Morihisa JM: Glutamatergic abnormalities in Alzheimer's disease and a rationale for clincal trials with L-glutamate. Clin Neuropharmacol 1988:11:18-35.
8. Foster A: Physiology and pathophsysiology of excitatory amino acid neurotransmitlcr systems in relation to Alzheimer's disease. Adv Neurol 1990:51:11:97-102.
9. 3H]TCP binding in Alzheimer’s disease. Neu-rosci Lett 1987:74:371-376.
10. 3H]MK 801 binding in Alzheimer’s disease. Neuro sci Lett 1988;93:225-230.
11. 3H]3-((±)-2-car-boxypiperazin-4-vl)propyl-1 -phosphon ic acid (PH CPP): Receptor status in Alzheimer’s disease brains. Eur J Pharmacol 1992:225:195- 201.
12. Ginsberg L, Alack JR, Rapoport SI, Gershfeld NL: Regional specificity of membrane instability in Alzheimer’s disease brain. Brain Res 1993:615:355-357.
13. Scheuer K, Stoll S, Paschkc U, Weigel R, Mueller WE: N-methyl-D-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging. Pharmacol Biochcm Be-hav 1995:50:65-70.
14. Scheuer K, Rostock A, Bartsch R, Koch S, Mueller WE: Alterations of the properties of brain membranes as a central mechanism for the cognitive decline in aged rats. Naunvn Schmiedebergs Arch Pharmacol 1995; 351 (suppl):627.
15. Forstl H, Bums A, Levy R, Cairns N, Luthert P, Lantos P: Neurologic signs in Alzheimer’s disease: Results of a prospective clinical and ncuropathologic study. Arch Neurol 1992;49; 1038-1042.
16. 3H-la-belled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 1987;84:7744-7748.
17. 3H]MK-801 binding: evidence for access to closed and open N-mcthyl-Z)-aspartate receptor channels. Mol Pharmacol 1989:35:387-393.
18. Munson P, Rodbard D: Ligand: A versatile computerized approach for characterization of ligand binding systems. Anal Biochem 1980; 107:220-239.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with the Folin phenol reagent. J Biol Client 1951:193:265-275.
20. Heron DS, Shinitzky M, Hershkowitz M, Samuel D: Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Nat Acad Sci USA 1980:77:7463- 7467.
21. Lakowiez J R: Principles of Fluorescence Spectroscopy. New York, Plenum Press, 1983.
22. Procter AW, Stirling JM, Stralinann GC, Cross AJ, Bowen DM: Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phcnydidinc receptor complex in patients with Alzheimer’s disease. Neurosci Lett 1989:101: 62-66.
23. 3H-TCP binding sites in Alzheimer’s disease brains. Brain Res 1988;462:76-82.
24. 3H] N - [I - (2 - thienyl)cyclohexyl] - 3.4 - pipcri -dine (('H)TCP) binding in human frontal cortex: Decreases in Alzheimer-Type dementia. J Neurochcm 1990;54:526-532.
25. Brooksbank BWL, Martinez M: Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease. Mol Chcm Ncuropa-thol 1989:11:157-185.
26. Hajimohammadreza I, Brammer M: Brain membrane fluidity and lipid peroxidation in Alzheimer’s disease. Neurosci Lett 1990:112: 333-337.
27. Jellinger K, Kienzl E, Puchinger L, Stachel-berger H: Changes of phospholipids in Alzheimer's disease brain; in Corain B. Iqbal K. Nicolini M, Winblad B, Wisniewski H. Zatta P (eds): Alzheimer's Disease: Advances in Clinical and Basic Research. New York. Wiley. 1993. pp 315-323.
28. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG; Evidence for changes in the Alzheimer’s disease brain cortical membrane structure mediated by cholesterol. Ncu-robiol Aging 1992; 13:413-419.
29. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wuttman RJ: Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 1992:89:1671-1675.
30. Zubenko GS: Hippocampal membrane alteration in Alzheimer's disease. Brain Res 1986: 385:115-121.